Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 6Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 39Lymphoma 34Lymphoma, Follicular 24Lymphoma, Non-Hodgkin 23Lymphoma, Mantle-Cell 19Lymphoma, B-Cell 16Leukemia, Lymphocytic, Chronic, B-Cell 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Multiple Myeloma 15Burkitt Lymphoma 14Lymphoma, B-Cell, Marginal Zone 13Hodgkin Disease 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Large-Cell, Anaplastic 8Glioma 8Neuroectodermal Tumors, Primitive, Peripheral 7Neuroblastoma 7Mycosis Fungoides 7Lymphoma, T-Cell 7Histiocytosis, Langerhans-Cell 7Wilms Tumor 6Waldenstrom Macroglobulinemia 6Sarcoma 6Rhabdoid Tumor 6Medulloblastoma 6Lymphoma, T-Cell, Cutaneous 6Hepatoblastoma 6Ependymoma 6Rhabdomyosarcoma 5Osteosarcoma 5

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Magnetic Resonance Spectroscopy × Lymphoid × Clear all
NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
50 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡